#Towards widespread access to messenger RNA (mRNA) vaccines!

A licensing agreement between SATT Aquitaine and Nexbiome Therapeutics has been signed to exploit an innovative technology developed by a team from the I2M research laboratory (University of Bordeaux, CNRS, Bordeaux INP, Arts et Métiers) and a team from UTCBS (Université Paris Cité, CNRS, Inserm).

This innovation is based on a unique method of RNA stabilization, presented in tablet form that can be stored at room temperature, facilitating oral administration.
The ProteRNA project: offering vaccines in tablet form

The ProteRNA project combines the pharmaceutical process engineering skills of Professor Pierre Tchoreloff’s team at the Institut de Mécanique et d’Ingénierie (I2M, Université de Bordeaux, CNRS, Bordeaux INP, Arts et Métiers) with those of Virginie Escriou, Research Director at the Unité des Technologies Chimiques et Biologiques pour la Santé (Université Paris Cité, CNRS, Inserm).

The invention involves the manufacture of a mucoadhesive tablet containing a nucleic acid vector (interfering RNA, mRNA) capable of triggering an immune response after administration in the oral cavity. Despite the technological challenges associated with shaping processes such as freeze-drying and compression, this dry tablet form offers several advantages:

oral administration,
significant stability of the pharmaceutical form
simplified deployment of vaccination on a large scale
greater patient comfort
easier logistics thanks to the tablet form of the treatment.